Back to results
US 2022/0017624 A1Published application
Anti-alpha-4-beta-7 antibodies
AssigneeAbbVie Inc.
InventorsJing Min, Teresa (Iok-Chan) Ng, Lorenzo Benatuil, Jacqueline Bixby, Tatyana Dekhtyar, Feng Dong, Axel Hernandez, Jr., Preethi Krishnan, Liangjun Lu, Federico Mensa, Renee Miller, Gautam Sahu
Life of this patent
Estimating the term…
Abstract
The present disclosure provides anti-α4β7 antibodies that bind human α4β7, their methods of making, and their uses to treat patients with HIV infection.
Claims17
An anti-human α4β7 antibody which comprises (i) a VH chain region comprising three CDRs;
- and (ii) a VL chain region comprising three CDRs, wherein:
- (SEQ ID NO:
- 72)
- VH CDR #1 is GFNIKNTYMH;
- (SEQ ID NO:
- 73)
- VH CDR #2 is RIDPAKGHTEYAPKFLG;
- (SEQ ID NO:
- 74)
- VH CDR #3 is VDV;
- (SEQ ID NO:
- 75)
- VL CDR #1 is HASQDISDNIG;
- (SEQ ID NO:
- 76)
- VL CDR #2 is HGTNLED;
- and
- (SEQ ID NO:
- 77)
- VL CDR #3 is VQYAQFPWT.
17 more elements
A polynucleotide comprising a nucleotide sequence encoding an anti-human α4β7 antibody, wherein the antibody comprises (i) a VH chain region comprising three CDRs;
- and (ii) a VL chain region comprising three CDRs, wherein:
- (SEQ ID NO:
- 72)
- VH CDR #1 is GFNIKNTYMH;
- (SEQ ID NO:
- 73)
- VH CDR #2 is RIDPAKGHTEYAPKFLG;
- (SEQ ID NO:
- 74)
- VH CDR #3 is VDV;
- (SEQ ID NO:
- 75)
- VL CDR #1 is HASQDISDNIG;
- (SEQ ID NO:
- 76)
- VL CDR #2 is HGTNLED;
- and
- (SEQ ID NO:
- 77)
- VL CDR #3 is VQYAQFPWT.
17 more elements
Dependencies are inferred from the claim text.